Clinical Trial Update: Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating neoadjuvant durvalumab with gemcitabine/cisplatin and adjuvant durvalumab for muscle-invasive bladder cancer is active-not-recruiting, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: AstraZeneca | Conditions: Muscle Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-07-03